BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28735458)

  • 1. Development of a vestibular schwannoma tumor slice model for pharmacological testing.
    Nickl V; Fakler J; Ziebolz D; Rumpel C; Stabenow L; Bernhagen J; Rampeltshammer E; Ernestus RI; Löhr M; Gugel I; Matthies C; Monoranu CM; Hagemann C; Breun M
    J Neurosci Methods; 2024 May; 405():110082. PubMed ID: 38387803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.
    Zhang N; Gao X; Zhao Y; Datta M; Liu P; Xu L
    J Rare Dis Res Treat; 2016; 1(2):51-55. PubMed ID: 28191549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.
    Vitte J; Gao F; Coppola G; Judkins AR; Giovannini M
    Nat Commun; 2017 Aug; 8(1):300. PubMed ID: 28824165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Critical Overview of Targeted Therapies for Vestibular Schwannoma.
    Tamura R; Toda M
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas.
    Van Gompel JJ; Agazzi S; Carlson ML; Adewumi DA; Hadjipanayis CG; Uhm JH; Olson JJ
    Neurosurgery; 2018 Feb; 82(2):E52-E54. PubMed ID: 29309638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An unusual finding of an anaplastic meningioma in NF2-related schwannomatosis.
    Adelhoefer SJ; Feghali J; Rajan S; Eberhart CG; Staedtke V; Cohen AR
    Childs Nerv Syst; 2024 Mar; ():. PubMed ID: 38451298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting.
    Hintelmann K; Kriegs M; Rothkamm K; Rieckmann T
    Front Oncol; 2020; 10():1260. PubMed ID: 32903756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare Primary Central Nervous System Tumors in Adults: An Overview.
    Franceschi E; Frappaz D; Rudà R; Hau P; Preusser M; Houillier C; Lombardi G; Asioli S; Dehais C; Bielle F; Di Nunno V; van den Bent M; Brandes AA; Idbaih A;
    Front Oncol; 2020; 10():996. PubMed ID: 32676456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.
    Messerli SM; Prabhakar S; Tang Y; Mahmood U; Giovannini M; Weissleder R; Bronson R; Martuza R; Rabkin S; Breakefield XO
    Hum Gene Ther; 2006 Jan; 17(1):20-30. PubMed ID: 16409122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of neurofibromatosis-associated tumours.
    Lin AL; Gutmann DH
    Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
    Paldor I; Abbadi S; Bonne N; Ye X; Rodriguez FJ; Rowshanshad D; Itzoe M; Vigilar V; Giovannini M; Brem H; Blakeley JO; Tyler BM
    J Neurooncol; 2017 Oct; 135(1):47-56. PubMed ID: 28735458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced RAC1 activity inhibits cell proliferation and induces apoptosis in neurofibromatosis type 2(NF2)-associated schwannoma.
    Wang Y; Wang B; Li P; Zhang Q; Liu P
    Neurol Res; 2017 Dec; 39(12):1086-1093. PubMed ID: 28934903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral nerve sheath tumors in Neurofibromatosis Type 2: Surgical and histopathologic features.
    Mehta GU; Huynh H; Lekovic GP
    Clin Neurol Neurosurg; 2020 Mar; 190():105649. PubMed ID: 31881415
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.